Oral Small Molecule Therapeutics
•249 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (249)
%
| Company | Market Cap | Price |
|---|---|---|
|
Lead assets NX-5948 and NX-2127 are oral small molecule therapeutics (BTK degraders), fitting the 'Oral Small Molecule Therapeutics' category.
|
$746.15M |
$9.76
+0.51%
|
|
Vafseo (vadadustat) is Akebia's core product and is an oral small-molecule therapeutic (HIF-PHI) for CKD-related anemia, aligning with the 'Oral Small Molecule Therapeutics' tag.
|
$722.25M |
$2.75
-4.84%
|
|
Ampreloxetine is an orally administered small-molecule therapeutic in Phase 3, representing a core product category for Theravance Biopharma.
|
$699.52M |
$13.99
-3.12%
|
|
TYRA's lead programs TYRA-300/TYRA-430 are oral small-molecule therapeutics targeting FGFR, representing major product category for the company.
|
$689.72M |
$12.97
+3.10%
|
|
ERAS-0015 and ERAS-4001 are small molecule–type therapies (pan-RAS molecular glue and pan-KRAS inhibitor), and naporafenib is a pan-RAF inhibitor, representing major oral small molecule cancer drugs.
|
$685.56M |
$2.42
+13.08%
|
|
TERN's pipeline consists of small-molecule, oral therapeutics (e.g., TERN-701 and TERN-601), classifying the company under Oral Small Molecule Therapeutics.
|
$680.36M |
$7.61
-2.31%
|
|
Anaphylm and Libervant use oral/buccal film delivery, representing the Oral Small Molecule Therapeutics category.
|
$649.60M |
$6.54
-2.24%
|
|
Development of small-molecule degraders positions GLUE in Oral Small Molecule Therapeutics.
|
$617.56M |
$10.04
+17.02%
|
|
KP1077 is an oral small-molecule therapeutic targeting IH/narcolepsy, aligning with the Oral Small Molecule Therapeutics category.
|
$602.02M |
$11.01
+0.18%
|
|
TPOXX is delivered as an oral formulation (capsule) and IV form, but the oral product anchors the company's position in the Oral Small Molecule Therapeutics category.
|
$587.25M |
$8.22
-2.72%
|
|
KalVista's EKTERLY (sebetralstat) is an orally delivered small molecule therapeutic approved for acute HAE attacks, directly matching the 'Oral Small Molecule Therapeutics' investable theme.
|
$574.47M |
$11.50
-2.54%
|
|
Lead candidate soquelitinib is an oral small molecule therapeutic, representing Corvus's core product line.
|
$569.88M |
$7.39
+11.30%
|
|
Pipeline centers on oral small-molecule therapeutics, including PROTAC degraders, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$548.90M |
$7.52
-2.59%
|
|
Lexicon's pipeline consists of oral small-molecule therapeutics (pilavapadin LX9211, LX9851, sotagliflozin) and it generates revenue from INPEFA, classifying as an oral small-molecule therapeutics business.
|
$541.14M |
$1.49
-10.24%
|
|
KHINDIVI (ET-400) and other oral formulations (ET-600) indicate a core focus on oral small molecule/oral therapeutics as a major product format.
|
$534.47M |
$19.93
+0.66%
|
|
Seralutinib is a small-molecule therapeutic drug in development for pulmonary hypertension, representing a core drug modality.
|
$518.25M |
$2.28
-10.59%
|
|
Rigel commercializes oral small-molecule therapeutics, including SYK, IDH1, and RET inhibitors, making this its core product category.
|
$503.65M |
$28.18
-0.77%
|
|
Esperion directly manufactures and sells oral small-molecule therapeutics (NEXLETOL and NEXLIZET).
|
$501.44M |
$2.53
+2.85%
|
|
Fulcrum's lead asset pociredir is an oral small molecule therapeutic, the core product category the company develops and would commercialize.
|
$485.27M |
$8.99
-7.37%
|
|
Pipeline and approved therapies are oral small molecule therapeutics (avutometinib/defactinib; VS-7375).
|
$470.91M |
$8.57
-7.45%
|
|
LY T-100 is an oral small molecule therapeutic (deupirfenidone) for IPF, representing a major product category for Celea Therapeutics.
|
$464.27M |
$18.00
|
|
Tivumecirnon is an oral small-molecule CCR4 antagonist, fitting Oral Small Molecule Therapeutics.
|
$443.00M |
$26.79
-10.52%
|
|
The pipeline includes small-molecule assets (e.g., ENT1 inhibitors, PTPN1/2 inhibitors, and A2A receptor antagonists) that fall under Oral Small Molecule Therapeutics.
|
$388.48M |
$10.15
|
|
VG-3927 is an oral small molecule therapeutic (TREM2 agonist) with PK/PD data supporting once-daily dosing.
|
$375.71M |
$8.05
|
|
Icosapent ethyl is a small molecule oral therapeutic marketed by Amarin; represents a key pharmaceutical product category.
|
$374.93M |
$18.23
-5.35%
|
|
Morphomer small molecules inhibit protein aggregation (Tau/alpha-synuclein), a major oral small molecule therapeutics category.
|
$354.43M |
$3.55
+0.28%
|
|
Lead candidate ARD-101 is an oral small-molecule therapeutic targeting TAS2R gut receptors to induce satiety, directly aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$352.78M |
$16.26
-1.99%
|
|
TN-301 is a small-molecule therapeutic (HDAC6 inhibitor), mapped to Oral Small Molecule Therapeutics.
|
$341.60M |
$2.10
-5.19%
|
|
ANX1502 is an oral small molecule inhibitor, representing an oral small-molecule therapeutic program.
|
$340.11M |
$3.10
-4.91%
|
|
Includes oral small molecule RASP modulators (e.g., ADX-629) and other systemic oral candidates in the pipeline.
|
$330.02M |
$5.51
-4.67%
|
|
Tradipitant (motion sickness) and PONVORY (ponesimod) are oral small-molecule therapeutics across neurology and autoimmune contexts.
|
$312.94M |
$5.31
-3.80%
|
|
Alvelestat is an oral small-molecule therapeutic; fits the OrAL Small Molecule Therapeutics category.
|
$311.64M |
$1.96
-6.67%
|
|
Galectin Sciences LLC aims to develop oral galectin-3 inhibitors, representing a substantial small-molecule therapeutics program.
|
$298.74M |
$4.72
-1.05%
|
|
BMB-101 and pipeline are small-molecule therapeutics; classify as Oral Small Molecule Therapeutics.
|
$282.52M |
$63.29
+2.58%
|
|
NERLYNX and the alisertib pipeline are orally administered small-molecule therapeutics for cancer, fitting the Oral Small Molecule Therapeutics category.
|
$254.15M |
$5.12
-2.29%
|
|
Directly produces and develops oral small molecule therapeutics (NLRP3 inhibitors) for autoimmune, inflammatory, and neuroinflammatory diseases.
|
$253.33M |
$3.56
-7.77%
|
|
Lanifibranor is Inventiva's lead asset, an orally administered small molecule therapeutic in Phase 3 for MASH, representing the core product focus.
|
$238.77M |
$4.55
-6.19%
|
|
RSV programs Zelicapavir and EDP-323 are oral small-molecule therapeutics, fitting the 'Oral Small Molecule Therapeutics' category.
|
$235.57M |
$11.02
-4.26%
|
|
ESK-001 and A-005 are oral small-molecule TYK2 inhibitors, a core direct product category.
|
$224.15M |
$4.29
+4.25%
|
|
Atebimetinib is an oral small-molecule therapeutic being developed for oncology.
|
$220.59M |
$6.13
-2.23%
|
|
NEO212 is a bio-conjugated small molecule with oral administration, aligning with the Oral Small Molecule Therapeutics category.
|
$219.38M |
$11.53
-1.11%
|
|
GNFT's core business is oral small-molecule therapeutics (elafibranor in PBC; additional drug candidates GNS561 and VS-01) across liver diseases.
|
$212.11M |
$4.25
-2.29%
|
|
Oral Small Molecule Therapeutics: Pipeline includes oral covalent ITK/JAK3 inhibitor ATI-2138 for immuno-inflammatory diseases.
|
$207.90M |
$1.90
-1.04%
|
|
BioAge's lead programs (BGE-102 and APJ agonists) are oral small-molecule therapeutics for obesity/metabolic disease, directly describing their product category.
|
$191.80M |
$5.35
-2.01%
|
|
SLS009 is a small-molecule, CDK9 inhibitor administered orally, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$190.58M |
$1.91
-1.04%
|
|
CRB-913 is a peripherally restricted CB1 inverse agonist, representing an oral small-molecule obesity therapy.
|
$190.16M |
$15.54
-2.08%
|
|
Lead programs are orally bioavailable small-molecule degraders (MonoDACs/BiDACs), aligning with Oral Small Molecule Therapeutics.
|
$171.84M |
$2.42
-6.20%
|
|
Emrosi is an oral small molecule therapeutic for rosacea, representing Journey Medical's core product avenue.
|
$169.83M |
$7.29
+0.41%
|
|
TNX-102 SL is a non-opioid, small-molecule therapeutic formulated as a sublingual tablet for fibromyalgia.
|
$155.21M |
$21.19
-4.46%
|
|
Elraglusib is a small-molecule therapeutic (IV with an oral formulation in development) targeting cancer, fitting the major product category of oral small-molecule therapeutics as a primary drug class.
|
$152.84M |
$7.79
-4.06%
|
|
Pipeline includes small-molecule CNS therapeutics (e.g., ALTO-300, ALTO-100/ALTO-101) aimed at depression and cognitive impairment.
|
$152.69M |
$5.64
-6.47%
|
|
Onvansertib is an oral small-molecule therapeutic, aligning with the tag for oral small molecule therapeutics.
|
$147.02M |
$2.21
-7.14%
|
|
AVTX-6 is described as an mTORC1/2 inhibitor (a small molecule), supporting a classification under Oral Small Molecule Therapeutics.
|
$145.09M |
$13.40
+3.47%
|
|
Simufilam is an oral small molecule therapeutic being developed as the company's lead drug candidate.
|
$144.44M |
$2.90
-2.84%
|
|
NXP900 is an oral small-molecule therapeutic (kinase inhibitor) directly developed by NVCT.
|
$140.86M |
$5.96
-0.33%
|
|
Z-endoxifen is an oral small-molecule therapeutic, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$139.50M |
$1.08
-7.69%
|
|
Lead programs are oral small molecule therapeutics (Aldose Reductase Inhibitors) targeting rare diseases.
|
$133.12M |
$0.94
-9.59%
|
|
IKT-001Pro is an oral small-molecule prodrug therapy (Imatinib derivative) being developed for PAH.
|
$120.43M |
$1.62
|
|
Azenosertib is an oral small-molecule therapeutic; tag as Oral Small Molecule Therapeutics.
|
$115.84M |
$1.59
-0.93%
|
|
Direct product: tebipenem HBr is an oral small-molecule therapeutic for complicated urinary tract infections, representing Spero Therapeutics' core asset.
|
$114.62M |
$2.05
+1.99%
|
|
ZUNVEYL is an oral small molecule prodrug therapy, categorized as Oral Small Molecule Therapeutics.
|
$112.46M |
$7.02
-7.99%
|
|
Achieve Life Sciences' direct product is cytisinicline, an oral small-molecule therapeutic for nicotine dependence, which corresponds to the 'Oral Small Molecule Therapeutics' investable theme.
|
$106.83M |
$3.08
-7.23%
|
|
ELYXYB (celecoxib oral solution) and GLOPERBA (colchicine oral solution) are oral small-molecule therapeutics directly produced and marketed by Scilex.
|
$103.79M |
$14.93
-15.27%
|
|
Lead product candidate is a small molecule therapeutic (selonabant) and the company developing oral small molecule therapeutics, with a strategic IV formulation for pediatric cannabis toxicity.
|
$95.32M |
$2.32
+2.20%
|
|
Immunic's pipeline consists of oral small-molecule therapeutics (IMU-838 and IMU-856) targeting immunology/autoimmune diseases, representing the core product category.
|
$86.09M |
$0.90
-2.61%
|
|
ATH434 is a small-molecule therapeutic candidate (likely oral) targeting neurodegenerative pathways, representing Alterity's core product.
|
$85.62M |
$0.01
|
|
Directly developing and marketing an oral small-molecule therapeutic (zervimesine/CT1812) for neurodegenerative diseases, fitting the 'Oral Small Molecule Therapeutics' category.
|
$83.69M |
$1.35
+1.50%
|
|
INF904 is an oral small molecule C5aR antagonist, fitting the Oral Small Molecule Therapeutics category.
|
$81.26M |
$1.38
-4.83%
|
|
Emrosi is an oral small molecule dermatology therapy associated with Journey Medical, a Fortress portfolio company.
|
$80.13M |
$2.71
-3.56%
|
|
INDOCIN is a small-molecule oral analgesic; the asset represents an oral small molecule therapeutic facing generic competition.
|
$79.98M |
$0.83
-4.47%
|
|
RP-3467 and RP-1664 are orally administered small-molecule oncology agents.
|
$77.20M |
$1.80
-1.10%
|
|
CardiolRx is an oral small-molecule therapeutic, fitting the Oral Small Molecule Therapeutics tag.
|
$73.00M |
$1.04
-4.59%
|
|
Oral small-molecule therapeutics platform (degraders and inhibitors) including SMARCA2/4, KAT6A, and CDK9 programs.
|
$71.14M |
$1.26
-9.35%
|
|
Lead program neflamapimod is an orally administered small molecule, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$70.93M |
$8.15
-5.12%
|
|
Lead program rezatapopt is a small molecule therapeutic pursued in oncology, fitting the 'Oral Small Molecule Therapeutics' category.
|
$70.66M |
$1.38
|
|
Cadisegliatin (TTP399) is an oral small molecule therapeutic in development by vTv Therapeutics, fitting the 'Oral Small Molecule Therapeutics' category.
|
$69.84M |
$21.86
|
|
Biomea Fusion is developing and planning to commercialize oral small-molecule therapeutics (e.g., icovamenib, BMF-650) for metabolic diseases, which directly maps to the 'Oral Small Molecule Therapeutics' category.
|
$63.12M |
$1.68
-5.62%
|
|
MN-166 and MN-001 are explicitly described as orally available small molecule therapeutics, matching the 'Oral Small Molecule Therapeutics' tag.
|
$62.78M |
$1.28
+3.23%
|
|
Lead assets are small molecule inhibitors (oral, non-biologic) in oncology, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$59.89M |
$1.91
+1.60%
|
|
DURECT's core offering is an oral small molecule therapeutic (larsucosterol) for alcohol-associated hepatitis.
|
$59.29M |
$1.91
|
|
AN4005 and AN9025 are oral small-molecule therapeutics targeting PD-L1 and pan-RAS pathways, respectively.
|
$57.88M |
$1.57
-7.10%
|
|
ALG-000184 (HBV) and ALG-055009 (MASH THR-β agonist) are oral small-molecule therapeutics, aligning with the Oral Small Molecule Therapeutics investable theme.
|
$57.66M |
$9.43
-8.18%
|
|
GT-02287 is a small-molecule therapeutic candidate (category: Oral Small Molecule Therapeutics) in Phase 1/1b for Parkinson's disease.
|
$56.75M |
$2.23
+16.15%
|
|
NRX-101 is an oral fixed-dose combination of small molecules, aligning with Oral Small Molecule Therapeutics.
|
$54.81M |
$3.17
-11.70%
|
|
Veru's lead products are oral small molecule therapeutics (enobosarm and sabizabulin), with enobosarm targeting weight loss and sabizabulin in late-stage ASCVD programs.
|
$54.68M |
$3.73
+3.61%
|
|
Lead assets (e.g., KB-0742) are small-molecule therapeutics intended for oral administration, matching Oral Small Molecule Therapeutics.
|
$53.65M |
$0.88
+1.49%
|
|
OLC and UNI-494 are both oral, small-molecule therapeutics (phosphate binder and prodrug respectively), placing UNCY in the 'Oral Small Molecule Therapeutics' category.
|
$53.56M |
$4.44
-6.72%
|
|
Ifetroban is CPIX's lead pipeline candidate and is a small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$51.62M |
$3.45
-2.27%
|
|
JOTROL enables an oral small molecule therapeutic platform, a core product line for the therapeutic pipeline.
|
$50.65M |
$1.53
-3.77%
|
|
Lead asset Telomir-1 is described as an oral small-molecule therapeutic.
|
$49.11M |
$1.65
-7.82%
|
|
Selinexor and the company’s pipeline are delivered as oral small‑molecule therapies (e.g., all‑oral regimens in MF), fitting the 'Oral Small Molecule Therapeutics' category.
|
$47.52M |
$5.50
-6.94%
|
|
EQ302 is described as an oral inhibitor for IL-15/IL-21, representing an oral small molecule therapeutic program.
|
$47.51M |
$1.45
+9.02%
|
|
ATH434 is a small-molecule therapeutic candidate (drug) in Phase 2 for MSA, fitting the 'Oral Small Molecule Therapeutics' category.
|
$45.65M |
$4.29
-1.38%
|
|
Buntanetap is an oral small-molecule therapeutic, the direct product category the company is developing.
|
$43.26M |
$2.22
-0.45%
|
|
Roxadustat is an oral small-molecule therapeutic (HIF-PHI) for anemia in lower-risk MDS.
|
$42.64M |
$10.55
-3.74%
|
|
Company focuses on discovery and development of oral small-molecule therapeutics powered by boron chemistry, with AN2-502998 for chronic Chagas disease and epetraborole for acute melioidosis, plus early oncology programs.
|
$39.23M |
$1.30
+2.36%
|
|
Lead programs are oral, small-molecule therapeutics (amezalpat and TPST-1495).
|
$38.30M |
$10.40
-2.07%
|
|
OKI-219 is a small molecule offered as an oral inhibitor, representing a major drug modality for the company.
|
$35.13M |
$2.60
+0.58%
|
|
CCX0722 is described as an oral small molecule obesity/weight management therapeutic.
|
$30.76M |
$1.07
-8.15%
|
|
SCYNEXIS is developing ibrexafungerp as an oral small-molecule antifungal; this directly aligns with the 'Oral Small Molecule Therapeutics' investable category.
|
$30.05M |
$0.77
-3.75%
|
Showing page 2 of 3 (249 total stocks)
Loading industry metrics...
Loading comparison data...
